📷 Image: Wikimedia Commons / Hibben00
Business
Biomarin shares jump on $490 million Alesta deal as analyst trims price target to $59
✍️ Asianet Newsable
🗓 19 Aug 2026, 02:38 AM
👁 1
Biomarin Pharmaceutical’s stock climbed after the company announced a deal with Alesta valued at up to $490 million, while a brokerage analyst lowered its price target to $59.
Biomarin Pharmaceutical Ltd. saw its shares rise on the news of a new agreement with Alesta that could be worth as much as $490 million. The market response was immediate, with the stock gaining momentum in early trading following the announcement.
The deal, described by the company as a strategic partnership, is expected to bring additional revenue streams, though the precise terms have not been fully disclosed. Analysts noted that the size of the transaction signals confidence in Biomarin’s pipeline and its ability to monetize upcoming products.
Despite the positive price movement, a leading brokerage analyst cut the firm’s price target to $59 per share. The revision reflects a more cautious outlook, taking into account broader market conditions and valuation considerations.
Investors will be watching how the Alesta collaboration unfolds and whether the revised target influences future trading patterns.
The deal, described by the company as a strategic partnership, is expected to bring additional revenue streams, though the precise terms have not been fully disclosed. Analysts noted that the size of the transaction signals confidence in Biomarin’s pipeline and its ability to monetize upcoming products.
Despite the positive price movement, a leading brokerage analyst cut the firm’s price target to $59 per share. The revision reflects a more cautious outlook, taking into account broader market conditions and valuation considerations.
Investors will be watching how the Alesta collaboration unfolds and whether the revised target influences future trading patterns.